Atopic dermatitis (AD) is a common inflammatory
skin disease for which few effective treatments are available.
Resolvin E1 (
RvE1; 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-
eicosapentaenoic acid) is an endogenous
lipid mediator derived from omega-3 fatty
eicosapentaenoic acid, which is a potent inhibitor of
inflammation. AD-like skin lesion was induced by repetitive skin contact with
DNFB in NC/Nga mice and the effects of
RvE1 were evaluated on the basis of histopathological findings of skin, ear swelling and
cytokine production of CD4(+) T cells.
Intraperitoneal injection of
RvE1 for one week after
DNFB challenge significantly lowered ear swelling and improved back skin lesions. In addition,
RvE1 significantly suppressed production of
interferon-gamma (IFN-γ) and
interleukin-4 (IL-4) by activated CD4(+) T cells and serum
IgE level. Furthermore,
RvE1 reduced
DNFB-induced infiltration of eosinophils, mast cells, CD4(+) T cells, and CD8(+) T cells in skin lesions. Therefore,
RvE1 may suppress the development of AD-like skin lesions in
DNFB-treated NC/Nga mice by reducing
IL-4 and IFN-γ of activated CD4(+) T cells and serum
IgE levels and infiltration of immune cells to skin lesion.